Loading...
Market
What will be the primary focus of psilocybin therapy in mental health by end of 2025?
2
Resolution / Starting Odds
Depression • 25%
Anxiety • 25%
PTSD • 25%
Addiction • 25%
Medical journals and healthcare policy reports
Story
Psilocybin Therapy Cuts Depression by Over 70% in COVID Healthcare Workers
Dec 5, 2024, 04:07 PM
A study published by the American Medical Association has found that psilocybin therapy, derived from magic mushrooms, led to a significant and sustained reduction in symptoms of depression among frontline healthcare workers, including doctors and nurses, who served during the COVID-19 pandemic. The therapy reduced depression scores by over 70%, compared to a 30% reduction observed with a placebo. Participants experienced an average drop in depression scores, underscoring the potential of psilocybin as a therapeutic option for mental health challenges faced by healthcare professionals.
View original story
Similar markets
Long-term mental health effects • 25%
Regulatory challenges • 25%
Ethical considerations • 25%
Lack of conclusive evidence • 25%
Depression • 25%
Anxiety • 25%
PTSD • 25%
Other • 25%
Depression • 25%
Anxiety • 25%
PTSD • 25%
Other • 25%
PTSD • 25%
Depression • 25%
Anxiety • 25%
Substance use disorders • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
High-dose psilocybin more effective • 25%
SSRIs more effective • 25%
Equally effective • 25%
No significant difference • 25%
Significant improvement • 25%
Moderate improvement • 25%
No significant change • 25%
Worsened condition • 25%